FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPRO	VAL
OMB Number:	3235-0287
Estimated average but	ırden
hours per response	0 '

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type	e Responses)															
Name and Address of Reporting Person * Catelani Michael				2. Issuer Name and Ticker or Trading Symbol Anixa Biosciences Inc [ANIX]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) (First) (Middle) C/O ANIXA BIOSCIENCES, INC., 3150 ALMADEN EXPRESSWAY, SUITE 250				3. Date of Earliest Transaction (Month/Day/Year) 03/10/2022						X	X Officer (give title below) Other (specify below) COO & CFO					
(Street) SAN JOSE,, CA 95118				4. If Amendment, Date Original Filed(Month/Day/Year)						_X_ F	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person					
(City))	(State)	(Zip)			Т	able I	- Non-Dei	ivative Sec	ırities Acc	quired,	luired, Disposed of, or Beneficially Owned				
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year	2A. Deemed Execution Date, any (Month/Day/Yea		ate, if ((4. Securities Acquire (A) or Disposed of (I (Instr. 3, 4 and 5)				ecurities Beneficially ng Reported		Ownership o	Beneficial Ownership	
							Code	e V Amount (A) or (D) Price		e				Instr. 4)	iistr. 4)	
			Table II					— ıired, Disp	osed of, or l	Beneficiall						
1. Title of Derivative Security (Instr. 3)		xercise (Month/Day/Year) any (Month/Day/Year) (Month/Day/Year)	4. 5. Num f Transaction Deriva Code Securit (Instr. 8) Acquir or Disp (D)		5. Numb Derivative Securities Acquired or Dispo (D) (Instr. 3,	er of ve s l (A) sed of	Expiration Date (Month/Day/Year)		d 7. To of U	7. Title and Amount of Underlying Securities (Instr. 3 and 4)			9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s	Ownershi Form of Derivativ Security: Direct (D or Indirect		
				Code	V	(A)	(D)	Date Exercisab	Expiration Date	n Title	e	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
						. ,	<u> </u>									

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Catelani Michael C/O ANIXA BIOSCIENCES, INC. 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE,, CA 95118			COO & CFO				

Signatures

/s/ Michael J. Catelani	03/11/2022			
**Signature of Reporting Person	Date			

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan.
- (2) The options vest and become exercisable in thirty-six (36) equal monthly installments beginning March 31, 2022.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.